IDH2 and astrocytoma (excluding glioblastoma): CNS WHO grade 3 patients were separated into low- and high-grade IDH-mutant astrocytoma groups based on DNA methylation profiling, eliminating the necessity for an intermediate histologic grade (Galbraith et al., 2024).